NEW YORK, September 19, 2017 /PRNewswire/ —
The hazards of pharmacology have hardly changed since Paracelsus, a famous Renaissance physician, astoundingly declared that it was only the dosage that separated a medicine from a poison, bundled with adverse side effects. Despite considerable advances in medicine, many medications are still as injurious as their Renaissance precursors. Nevertheless, recent developments in drug delivery technologies increasingly suggest that safer, more efficient treatment options are on the horizon. At the core of this potential are cannabinoids. Developments in this rapidly growing segment of the medical marijuana market are pioneered by a vast number of innovators, including Lexaria Bioscience Corp. (OTC: LXRP) (CSE: LXX) (LXRP Profile), GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals (NASDAQ: ZYNE),Cara Therapeutics (NASDAQ: CARA) and Philip Morris (NYSE: PM), all of which are invested in the cannabis space.
Research findings in the cannabinoid field continue to astonish and elate. In